id fellows course 2010 christian b. ramers, md, mph opportunistic infections
Post on 19-Dec-2015
215 views
TRANSCRIPT
![Page 1: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/1.jpg)
ID Fellows course 2010Christian B. Ramers, MD, MPH
Opportunistic Infections
![Page 2: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/2.jpg)
Learning Objectives
• Develop systematic approach to diagnosis of OI’s in immunocompromised patients
• Describe preferred initial therapy of select OI’s• Review CD4 cell count thresholds/risk of OI’s• Discuss timing of HAART in setting of acute OI
![Page 3: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/3.jpg)
Case #1: HPI
• 54 yo Latino male with fever, diarrhea, cough– Presented to Pioneer Square clinic 5/09 with 1
month of fever and diarrhea, 2 months dry cough– HIV Ab and Western Blot positive in clinic– 20 lbs involuntary weight loss– 10+ watery stools/day– Cough mostly dry, some scant whitish mucus
• What are you worried about?
![Page 4: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/4.jpg)
Case #1: Additional History• Risk Factor: MSM exclusively, 3 lifetime partners• No prior illnesses/hospitalizations • Rare social EtOH, Denies tobacco, IVDU• Born & raised in Cuernavaca, Mexico • 1986 emigrated to Phoenix, AZ• 1998 moved to Minneapolis, MN• 5/2009 moved to Seattle• Worked odd jobs in AZ, MN, now homeless
![Page 5: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/5.jpg)
Case #1: PEX
• Vitals: 38.9, 99, 18, 113/72, SaO2 98% on RA• Gen: thin Latino man, mild distress• Chest: inspiratory crackles B bases• CV: RRR no murmurs• Abd: scaphoid, tympanetic, liver edge palpable
at R costal margin, no splenomegaly• Extr: No edema• Skin: No lesions, no rash
![Page 6: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/6.jpg)
Initial Work-up?
![Page 7: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/7.jpg)
CXR 6/1/09
![Page 8: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/8.jpg)
Case #1: Initial Labs
• Initial CBC: WBC 4.46, Hct 32, Plt 102• LFT’s: AST/ALT 97/52; Alb 2.4, LDH 248• CD4: 21 (3%), HIV VL 580,000; genotype pending
What else do you want?
AFB sputum smears x 3: NEGATIVE
![Page 9: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/9.jpg)
CT 6/2/09
![Page 10: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/10.jpg)
CT 6/2/09
![Page 11: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/11.jpg)
CT 6/2/09
![Page 12: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/12.jpg)
CT 6/2/09
![Page 13: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/13.jpg)
CT 6/2/09
![Page 14: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/14.jpg)
How would you approach this patient?
![Page 15: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/15.jpg)
Case #1: DDx – undifferentiated fever
• TB• MAC• CMV• Bartonella• Lymphoma• Histoplasmosis• Cryptococcus• Leishmania• (Malaria, Penicillium spp, Amebic liver abscess)
USA Spain India
-- 42% 63%
31% 14% --
11% -- --
8-18% -- --
-- -- --
7% -- 5%
-- -- 10%
-- 14% --
![Page 16: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/16.jpg)
Case #1: DDx – Chronic Watery Diarrhea
• Giardia• CMV• MAC• Cryptosporidium• Microsporidium• Cyclospora• Isospora• ‘HIV enteropathy’
• Salmonella• Shigella • Campylobacter• E. coli (EAEC)• C. difficile• E. histolytica
![Page 17: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/17.jpg)
Case #1: DDx – dry cough w/ nodules
• TB• KS• Lymphoma• Histoplasmosis• Coccidiomycosis• Legionella• Rhodococcus• Cryptococcus (var grubii, var gattii)
• Nocardia• Toxoplasma• MAC• M. kansasii• Pneumocystis• CMV
![Page 18: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/18.jpg)
Case #1: Follow-up Labs • Stool Studies:
– C. difficile A&B toxin NEGATIVE– 6/1 O&P (concentrated/trichrome): NEGATIVE– 6/2 O&P (concentrated/trichrome): NEGATIVE– 6/2 Giardia Ag: NEGATIVE– 6/3 Modified Acid-fast: POSITIVE
source: www.hivwebstudy.org
![Page 19: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/19.jpg)
Cryptosporidiosis
source: www.hivwebstudy.org
![Page 20: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/20.jpg)
Cryptosporidiosis
MMWR April 10,2009; 58 (RR4): 1-206
• Etiology: Cryptosporidium parvum
• Presentation: • Self-limited diarrhea in normal
hosts• Worse in CD4 < 150: range
from foul-smelling bulky to watery ‘cholera-like’. Can also cause biliary, respiratory disease
• Pathophysiology: inflammation & villous atrophy malabsorption, increased permeability, solute flux into the gut lumen; rarely invasive
• Diagnosis: Usually missed by traditional ‘O&P’ exam (4-6 mm, similar to yeast); fluorescent or modified Acid-fast stain
![Page 21: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/21.jpg)
Cryptosporidiosis - Treatment
• Specific therapy usually not necessary• Some data for nitazoxanide for special cases
Preferred Alternative Comments
Initiate ART (AII) Nitazoxanide 500-1000 BID (CIII)
Paromomycin not recommended
Aggressive Oral and IV rehydration & electrolyte
replacement (AIII)
Symptomatic treatment of diarrhea (AIII)
Loperamide often helpful
MMWR 2009; 58 (RR4): 1-132
![Page 22: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/22.jpg)
Case #1: Follow-up Labs • Sputum for AFB negative x 3
• TB AMPLIFIED DIRECT TEST - Sputum POST BRONCH AFB POS SMEAR • Last Update: 06/11/09 12:14 Collected: 06/05/09 15:30• MTB Complex rRNA: POSITIVE
• AFB CULTURE W/STAIN - Sputum, Induced mucoid in cup • Last Update: 06/23/09 11:01 Collected: 06/02/09 13:00• AFB Stain: No acid fast bacilli seen (concentrated smear) by Auramine stain• Culture: Presumptive Mycobacterium tuberculosis complex isolated from broth only :
• AFB CULTURE W/STAIN - Sputum POST BRONCH in cup • Last Update: 07/07/09 10:13 Collected: 06/05/09 15:30• AFB Stain: Rare Acid Fast Bacilli by Auramine stain• Culture: 2+ Mycobacterium tuberculosis : Identification by DNA probe and phenotypic analyses
• 2+ MYCOBACTERIUM TUBERCULOSIS - AFB MGIT• Ethambutol (5 mcg/mL) S • Isoniazid (0.1 mcg/mL) S • Rifampin (1 mcg/mL) S • Streptomycin (1 mcg/mL) S
![Page 23: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/23.jpg)
Case #1: Clinical course
• Intensive IV fluid, nutrition, electrolytes• Started on RIPE• Developed pancytopenia, transaminitis• Many drug changes• Continuous fever
• Who wants to start HAART?
![Page 24: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/24.jpg)
ACTG 5164 – HAART in setting of Acute OI
• Entry OI’s: PJP (63%), Crypto (12%), Bacterial Infection (12%), Toxo (5%), Histo (4%), CMV (2%), MAC (2%), [Multiple 33%]
Zolopa A, et al PLoS One 2009; 4(5): 5575
Study Features
Protocol - N = 282 randomized and treated- Age > 13- ARV-naïve- Median CD4 = 29- OI’s presumed or confirmed- TB excluded!!- Composite 48 wk endpoint: Death, AIDS progression, VL < 50
Early ART: within 14 dof OI diagnosis
(n = 141)
Deferred ART: after OItreatment completed
(n = 141)
1x
![Page 25: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/25.jpg)
ACTG 5164 – HAART in setting of Acute OI
• HR 0.53 (95%CI 0.3-0.92) favoring early ARTZolopa A, et al PLoS One 2009; 4(5): 5575
![Page 26: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/26.jpg)
Case #1: Clinical course
• Patient had remained relatively stable on RIPE• Discharged with Madison Clinic f/u• HAART deferred due to transaminitis, ongoing
fevers, diagnostic uncertainty
• Presented to Madison Clinic for initial visit: febrile to 39.0, AST/ALT 150’s
• Now what?
![Page 27: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/27.jpg)
Case #1: Follow-up Labs • Serum Histoplasma Ag (6/6/09): POSITIVE 36.0
• AFB CULTURE, BLD CULT BOTTLES - Blood Arm, Right Aerobic and anaerobic bottles • Last Update: 06/29/09 15:36 Collected: 06/03/09 13:23• Culture: No acid fast bacilli isolated in 26 days. Histoplasma capsulatum isolated from mycobacterial
broth : identification by sequence analysis .
• LOWER RESP FUNGAL W/DIR. EXAM - Bronchoalveolar Lavage No. 2 Lung, Right Middle Lobe Cloudy • Last Update: 07/06/09 11:12 Collected: 06/05/09 14:15• Stain for Fungus: No fungi seen• Culture: 2+ Presumptive Histoplasma capsulatum SEE BLOOD CULTURE 6/3/09 FOR CONFIRMATION
• AFB CULTURE, BLD CULT BOTTLES - Blood Arm, Left Yellow top tube • Last Update: 08/11/09 11:34 Collected: 06/06/09 07:45• Culture: Mycobacterium tuberculosis complex isolated from broth only Presumptive identification by
colonial morphology. : see sputum of 6/5/09 for susceptibilities Presumptive Histoplasma capsulatum isolated from mycobacterial broth
![Page 28: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/28.jpg)
Histoplasmosis• Etiology: Histoplasma capsulatum• Presentation:
• Acute: febrile pulmonary infection• Reactivation: fever, chills, wt loss, bone
marrow failure, anemia, high LFT’s, may have evidence of old disease on CXR
• Pathophysiology: Initially latent disease, with reactivation upon immunosuppresion
• Diagnosis: Direct visualization of fungus, culture, Serum or Urine Antigen test
• Mortality: low in immune competent; high in immunosuppressed.
• Risk Factors: dyspnea, plt < 100K, high LDH
![Page 29: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/29.jpg)
Edwards LB; Am Rev Repir Dis. 1969; 99(4):Suppl: 1-132
Histoplasma Distribution
![Page 30: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/30.jpg)
Mochi A and Edwards PQ; Bull WHO, 1952(5): 252-291
Histoplasma Distribution
![Page 31: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/31.jpg)
Histoplasmosis - TreatmentSyndrome Preferred Alternative Comments
Severe Disseminated
Liposomal Ampho B 3 mg/kg x 14 d (AI)
Ampho BABLC
Itraconazole 200 mg TID x 3d BID (AII)
Levels should be optained (AIII)
Less Severe Disseminated
Itraconazole 200 mg TID x 3 d BID (AII) Duration > 12 mos
Meningitis Liposomal Ampho B 5 mg/kg x 4-6 wks
Itraconazole 200 mg BID/TID x > 1 year
Treat until CSF normalizes
Long-term suppression
Itraconazole 200 mg QD
Recommended for CNS disease or any
relapse
MMWR 2009; 58 (RR4): 1-132
![Page 32: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/32.jpg)
Case #1: Resolution• Later dx’d with CMV gastritis, Late latent syphilis,
H.pylori gastritis (received PCN, Gancyclovir/Val-G, Amox/Clarithro/PPI)
• Complicated by ARF, LFT’s, pancytopenia
• Started HAART 9/09 (FTC/TDF+ATZ/r)– Developed 3 new liver masses, AST/ALT 200/175– Liver biopsy: granulomas, no growth (TB/Histo IRIS)
• Now doing well on HAART, INH/Ethambutol, Itraconazole, pentamidine (CD4 88, VL < 40)
![Page 33: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/33.jpg)
Case #1: Summary• Cryptosporidium is a common cause of watery
diarrhea in immunocompromised. Best diagnosed with Modified Acid-Fast Stain
• Immunocompromised patients often have multiple OI’s (sometimes 5!!)
• Evidence appears to support early initiation of HAART in the setting of select OI’s (ACTG 5164) but still handled case-by-case
• Beware of IRIS
![Page 34: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/34.jpg)
Ockam’s razor
Pluralitas non est ponenda sine neccesitate• “Plurality is not to be posited without necessity”Frustra fit per plura quod potest fieri per pauciora• “It is futile to do with more things that which can be done with fewer”
![Page 35: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/35.jpg)
Case #2: HPI
• 46 yo Caucasian Male 50 lbs wt loss, GI issues• Odynophagia for solids, diarrhea (5-10 loose,
foul-smelling BM’s/day)• Out of care x 3 years, previously seen in FL • On Atripla but resistant to ‘two of the three’• Stopped ARV’s because he felt well• Prescribed Raltegravir + Darunavir/Ritonavir +
Etravirine but never picked up
![Page 36: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/36.jpg)
Case #2: Additional History
• HIV dx’d 2002, risk: MSM• Previous Nadir CD4 76• HIV-related hx: thoracic zoster, KS posterior neck,
PJP, Oral/Esophageal Candidiasis, HIV wasting, esophageal ulcers, chronic diarrhea
• Worked as a flight attendant but lost job• Reports > 30 lifetime partners• Recently moved back to Whidbey Island w/mom
![Page 37: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/37.jpg)
Case #2: PEX• Vitals: 36.5, 76, 20, 110/78, SaO2 98% on RA, 66 kg (6’1”)• Gen: anxious cachectic Caucasian man, no distress• HEENT: temporal wasting, thrush on buccal
mucosa, OHL on lateral tongue, angular chelitis• Chest/CV: CTAB, RRR• Abd: scaphoid, no HSM, hyperactive BS• Extr: thin, with atrophy• Skin: scaly erythematous plaques on face
concentrated around eyebrows & ears
![Page 38: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/38.jpg)
What can you do on the 1st visit?
![Page 39: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/39.jpg)
Case #2: • Records pending, FL doc gave some via phone• CD4 27 (4%), VL 538,500• CBC: WBC 2.3, Hct 35, Plt 159• LFT’s normal, Cr 0.7• Stool studies:
– 6/2/10 O&P (concentrated/trichrome): NEGATIVE– 6/3/10 O&P (concentrated/trichrome): NEGATIVE– 6/2/10 Modified Acid Fast stain: NEGATIVE– 6/2 Giardia Ag: POSITIVE– 6/9/10 O&P (concentrated/trichrome): POSITIVE for G.
lamblia cysts and trophozoites
![Page 40: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/40.jpg)
Case #2: Stool Studies
Photo courtesy of Carolyn Wallis (HMC Microbiology)
![Page 41: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/41.jpg)
Case #2: Initial Management
• TMP/SMX DS – PJP prophylaxis• Azithromycin Qweek – MAC prophylaxis• Ketoconazole topical – for Seborrheic derm• (Metronidazole 250 TID x 5 d)• Fluconazole 100 mg PO QD x 3 wks (planned)• Sent Trofile assay, HIV genotype
![Page 42: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/42.jpg)
Candidiasis - TreatmentInfection Preferred Alternative Comments
Oral Fluconazole 100 mg QD (AI) x 7-14 d
Itraconazole 200 mg QD (BI)
Chronic Azoles may promote resistance
Clotrimazole 10 mg troche 5X/day
Posaconazole 400 PO BID x 1QD
Higher relapse w/ echinocandins
Nystatin susp 5 mL QID (BII)
Miconazole QD (BII)
Esophageal Fluconazole 100-400 mg QD x 14-21 d (AI)
Echinocandin: Mica-, Caspo-, Anidulafungin (BI)
Suppressive therapy not recommended
Itraconazole 200 mg QD x 14-21 d (AI)
Azole: Vori-, Posaconazole (BI)
Amphotericin B (BI)
MMWR 2009; 58 (RR4): 1-132
![Page 43: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/43.jpg)
Case #2:
• Returns 2 weeks later with improved diarrhea, but worsening odynophagia
• EGD scheduled urgently
• What’s your pre-EGD Differential Dx?
![Page 44: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/44.jpg)
Case #2: Ddx – Odynophagia • Esophageal Candidiasis• HSV• VZV• CMV• Aphthous ulcers• Gastric/Esophageal KS• Lymphoma• Severe H. pylori gastritis
![Page 45: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/45.jpg)
Case #2: EGD
Ulceration – mid-esophagus
![Page 46: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/46.jpg)
Case #2: EGD
Patchy erythema – mid-Antrum
![Page 47: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/47.jpg)
Case #2: Esophageal Biopsy
Granulation tissue, inflammation, rare inclusions
![Page 48: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/48.jpg)
Case #2: Esophageal Biopsy
CMV Inclusions
![Page 49: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/49.jpg)
Cytomegalovirus• Etiology: CMV – β-herpesvirus• Clinical Manifestations:
• Seroprevalence 60-70% in US, ~100% in Africa
• Mono-like ‘CMV syndrome’, esophagitis, colitis, interstitial pneumonitis, hepatitis, retinitis, meningoencephalitis, myocarditis
• Pathophysiology: After acute infection, cycles of latent/reactivated disease
• Diagnosis: Serology, Shell vial, serum PCR suggestive, but must demonstrate CMV in tissue to call disease
• Mortality: MAJOR cause of mortality in iatrogenically immunosupressed, most common congenital infection
![Page 50: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/50.jpg)
CMV Disease - TreatmentInfection Preferred Alternative Comments
RetinitisGCV intraocular
implant + Val-G 900 mg BID x 14-21 d
Foscarnet 60 mg/kg Q8 x 14-21 d
Initial Rx individualized based on lesion
Val-G 900 mg QD Cidofovir 5 mg/kg wk x 14 d
Can D/C maintenance when CD4> 100-150
Esophagitis/ Colitis
GCV or Foscarnet IV x 21-28 d (BII)
Maintenance therapy may not be necessary
Oral Val-G x 21-28 d if symptoms mild
Maintenance should be given for relapses
Pneumonitits GCV or Foscarnet IV CMV-Ig Histologically proven,
no role maintenance
CNS disease GCV AND Foscarnet IV until better
Maintenance Val-G + Foscarnet until
immune recovery
MMWR 2009; 58 (RR4): 1-132
![Page 51: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/51.jpg)
Case #2: Resolution• Received IV Ganciclovir BID x 21 days then
transitioned to Valganciclovir QD• Diarrhea and Odynophagia resolved• Started HAART with FTC/TDF + MVC + RAL• Admitted yesterday with new fevers!
![Page 52: ID Fellows course 2010 Christian B. Ramers, MD, MPH Opportunistic Infections](https://reader036.vdocument.in/reader036/viewer/2022062516/56649d2e5503460f94a059d6/html5/thumbnails/52.jpg)
Case #2: Summary• Being ‘out of care’ is bad• MSM have unique risk profile• Lower CD4 counts open the door to a broader
array of pathogens• We still see the ‘old AIDS-defining illnesses’